+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Hepatoprotective effects of pycnogenol in a rat model of non-alcoholic steatohepatitis



Hepatoprotective effects of pycnogenol in a rat model of non-alcoholic steatohepatitis



PhytoTherapy Research 26(10): 1572-1574



Oxidative stress is considered as a mechanism of hepatocellular injury in non-alcoholic steatohepatitis (NASH). Pycnogenol (PYC) is the natural plant extract from the bark of Pinus pinaster Aiton. and has potent antioxidant activities. We studied the protective effect of PYC on excessive fat accumulation in the liver fed a methionine-choline deficient (MCD) high-fat diet for 6 weeks. Pycnogenol (10 mg/kg body weight) was orally administered for 5 weeks. At the end of the experiment, blood and liver samples were collected and assessed for effects of PYC by histopathological and biochemical analyses. Histopathological analyses of liver tissues stained with Azan-Mallory showed hepatic macrovesicular steatosis and fibrosis in MCD-fed rats. Supplementation of PYC prevented this effect. Pycnogenol treatment significantly decreased the liver triglyceride and serum alanine amino transferase levels. Our results indicated that orally administered PYC may serve to prevent NASH-induced liver damage.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036332853

Download citation: RISBibTeXText

PMID: 22294490

DOI: 10.1002/ptr.4602


Related references

Hepatoprotective and immunomodulatory effects of infliximab on experimental alcoholic steatohepatitis. Eksperimental'naia i Klinicheskaia Farmakologiia 75(7): 36-39, 2012

Antioxidant and hepatoprotective effects of extract of ginkgo biloba in rats of non-alcoholic steatohepatitis. Saudi Medical Journal 31(10): 1114-1118, 2010

Hepatoprotective effects of geniposide in a rat model of nonalcoholic steatohepatitis. Journal of Pharmacy and Pharmacology 63(4): 587-593, 2011

Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evidence-BasedComplementaryandAlternativeMedicine2011:Nep164, 2011

Hepatoprotective effect of tamoxifen on steatosis and non-alcoholic steatohepatitis in mouse models. Journal of Toxicological Sciences 37(5): 931-942, 2012

Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects. European Journal of Pharmacology 588(2-3): 316-324, 2008

Beneficial Effects of Fermented Green Tea Extract in a Rat Model of Non-alcoholic Steatohepatitis. Journal of Clinical Biochemistry and Nutrition 44(3): 239-246, 2009

Protective effects of SP600125 in a diet-induced rat model of non-alcoholic steatohepatitis. Scandinavian Journal of Gastroenterology 44(11): 1356-1362, 2009

Comparison of clinical, biochemical and histological features of alcoholic steatohepatitis and non-alcoholic steatohepatitis in Asian Indian patients. Indian Journal of Pathology and Microbiology 53(3): 408-413, 2010

Comparative therapeutic effects of metformin and vitamin E in a model of non-alcoholic steatohepatitis in the young rat. European Journal of Pharmacology 604(1-3): 125-131, 2009

An Animal Model for the Juvenile Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. Plos one 11(7): E0158817, 2016

Regulation of transglutaminase-mediated hepatic cell death in alcoholic steatohepatitis and non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 27(Suppl. 2): 52-57, 2012

Antifibrotic effects of ambrisentan, an endothelin-A receptor antagonist, in a non-alcoholic steatohepatitis mouse model. World Journal of Hepatology 8(22): 933-941, 2016

A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease. Digestive and Liver Disease 46(11): 1008-1013, 2014